Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB2 known ✓ | P30411 | 3/20 | 0.35 |
| ▸ | ABL1 | P00519 | 2/20 | 0.32 |
| ▸ | RET | P07949 | 2/20 | 0.32 |
| ▸ | KDR | P35968 | 2/20 | 0.32 |
| ▸ | CDK7 | P50613 | 2/20 | 0.32 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.32 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | PAK4 | O96013 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22490329 | 0.79 | KDM4E (0.40) | ABL1RETKDRCDK7CDK5 | |
| SCHEMBL2721703 | 0.78 | GAA (0.41) | ABL1RETKDRCDK7CDK5 | |
| Hydrochloric Acid SCHEMBL4855839 | 0.73 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL2971825 | 0.72 | DYRK1A (0.39) | ABL1RETKDRCDK7CDK5 | |
| SCHEMBL5103470 | 0.72 | DYRK1A (0.39) | ABL1RETKDRCDK7CDK5 | |
| SCHEMBL7835407 | 0.72 | TDP1 (0.39) | ABL1RETKDRCDK7CDK5 | |
| SCHEMBL13607882 | 0.72 | SMN1; SMN2 (0.38) | KDM4EALDH1A1LMNAMAPTPKM | |
| SCHEMBL13607880 | 0.70 | ALPL (0.38) | KDRCDK5AURKBCLK4AURKA | |
| SCHEMBL855352 | 0.70 | DYRK1A (0.37) | ABL1RETKDRCDK7CDK5 | |
| Hydrochloric Acid SCHEMBL11380973 | 0.69 | BDKRB2 (0.43) | BDKRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317650-A1 | IMIDAZOPYRIDINE DERIVATIVES USEFUL AS INOS INHIBITORS | NYCOMED GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| US-20100280002-A1 | AMINOPYRIDINE-DERIVATIVES AS INDUCTIBLE NO-SYNTHASE INHIBITORS | ALTANA PHARMA AG (DE) | 2010-11-04 | — | — | US | disclosed |
| US-7790710-B2 | Imidazopyridine derivatives useful as iNOS inhibitors | NYCOMED GMBH (DE) | 2010-09-07 | — | — | US | disclosed |
| US-7781453-B2 | Aminopyridine-derivatives | ALTANA PHARMA AG (DE) | 2010-08-24 | — | — | US | disclosed |
| EP-1866306-B1 | IMIDAZOPYRIDINE DERIVATIVES USEFUL AS INOS INHIBITORS | NYCOMED GMBH (DE) | 2009-06-17 | — | — | EP | disclosed |
| US-20090131399-A1 | Imidazopyridine Derivatives Useful as iNOS Inhibitors | NYCOMED GMBH (DE) | 2009-05-21 | — | — | US | disclosed |
| US-20080176894-A1 | Used as nitric oxide synthase inhibitors; treating acute inflammatory disease with such as 2-[2-(2-amino-4-methylpyridin-6-yl)ethyl]-3H-imidazo[4,5-b]pyridine | ALTANA PHARMA AG | 2008-07-24 | — | — | US | disclosed |
| WO-2008031788-A1 | AMINOAZEPINE DERIVATIVES AS HIGHLY EFFICIENT INHIBITORS OF THE INDUCIBLE NITRIC OXIDE SYNTHASE | NYCOMED GMBH (DE) | 2008-03-20 | — | — | WO | disclosed |
| US-7317021-B2 | Aminopyridine-derivatives as inductible no-synthase inhibitors | ALTANA PHARMA AG (DE) | 2008-01-08 | — | — | US | disclosed |
| EP-1866306-A1 | IMIDAZOPYRIDINE DERIVATIVES USEFUL AS INOS INHIBITORS | Nycomed GmbH (DE) | 2007-12-19 | — | — | EP | disclosed |
| US-20070043072-A1 | Aminopyridine-derivatives as inductible no-synthase inhibitors | ALTANA PHARMA AG (DE) | 2007-02-22 | — | — | US | disclosed |
| WO-2006103255-A1 | IMIDAZOPYRIDINE DERIVATIVES USEFUL AS INOS INHIBITORS | NYCOMED GMBH (DE) | 2006-10-05 | — | — | WO | disclosed |
| EP-1670798-A1 | AMINOPYRIDINE-DERIVATIVES AS INDUCTIBLE NO-SYNTHASE INHIBITORS | Altana Pharma AG (DE) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005061496-A1 | AMINOPYRIDINE-DERIVATIVES AS INDUCTIBLE NO-SYNTHASE INHIBITORS | ALTANA PHARMA AG (DE) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043072-A1 | Aminopyridine-derivatives as inductible no-synthase inhibitors | NOS2, NOS1, NOS3 | BDKRB2 1132/4885ABL1 619/4885RET 1167/4885 |
| US-20100317650-A1 | IMIDAZOPYRIDINE DERIVATIVES USEFUL AS INOS INHIBITORS | NOS2, NOS1, ARG1 | BDKRB2 608/4885ABL1 1062/4885RET 1000/4885 |
| US-20090131399-A1 | Imidazopyridine Derivatives Useful as iNOS Inhibitors | NOS2, NOS1, ARG1 | BDKRB2 608/4885ABL1 1062/4885RET 1000/4885 |
| US-20100280002-A1 | AMINOPYRIDINE-DERIVATIVES AS INDUCTIBLE NO-SYNTHASE INHIBITORS | NOS2, NOS1, NOS3 | BDKRB2 1132/4885ABL1 619/4885RET 1167/4885 |
| US-20080176894-A1 | Used as nitric oxide synthase inhibitors; treating acute inflammatory disease with such as 2-[2-(2-amino-4-methylpyridin-6-yl)ethyl]-3H-imidazo[4,5-b]pyridine | NOS2, NOS1, NOS3 | BDKRB2 266/4885ABL1 616/4885RET 2781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.